Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held this year in the vibrant city ...

Merck’s Phase III KEYNOTE-B96 trial shows significant overall and progression-free survival gains with Keytruda plus ...

of subcutaneous Keytruda given alone in relapsed or refractory classical Hodgkin lymphoma and relapsed or refractory primary mediastinal large B-cell lymphoma. Another phase 2 trial will gauge ...

Seagen has a long history in ADC development, claiming FDA approval for Adcetris (brentuximab vedotin) as a treatment for classical Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL ...

A pooled analysis of individual data from 5 COG studies demonstrated that race/ethnicity has no significant effect on survival for children and AYAs with cancer receiving treatment on clinical trial.

Most clinical trials test new treatments only after cancer has relapsed and grown large enough to be detected on scans. The ...

Lymphomas belong to the group of malignant diseases of the immune system and mainly affect the organs of the lymphatic system ...

Lymphomas belong to the group of malignant diseases of the immune system and mainly affect the organs of the lymphatic system. Anaplastic large cell lymphoma (ALCL) belongs to the subgroup of ...

A systematic review and subsequent expert review gave comprehensive insight into prognostic factors for patients receiving ...